Sumatriptan succinate - Generic Drug Details

What are the generic sources for sumatriptan succinate and what is the scope of patent protection?

Sumatriptan succinate is the generic ingredient in eight branded drugs marketed by Meridian Medcl, Glaxosmithkline, Alembic, Antares Pharma Inc, Baxter Hlthcare Corp, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hikma, Norvium Bioscience, Onesource Specialty, Ph Health, Sandoz, Sun Pharm, Teva Parenteral, Teva Pharms Usa, Wockhardt Bio Ag, Zydus, Endo Operations, Currax, Tonix Meds, Teva Branded Pharm, Aurobindo Pharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Ipca Labs Ltd, Mylan, Orbion Pharms, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, Vkt Pharma, Watson Labs, and Zhejiang, and is included in forty-five NDAs. There are twenty-seven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sumatriptan succinate has two hundred and twenty-five patent family members in twenty-five countries.

There are seventeen drug master file entries for sumatriptan succinate. Thirty-seven suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for sumatriptan succinate

International Patents:	225
US Patents:	27
Tradenames:	8
Applicants:	37
NDAs:	45
Drug Master File Entries:	17
Finished Product Suppliers / Packagers:	37
Raw Ingredient (Bulk) Api Vendors:	116
Clinical Trials:	26
Drug Prices:	Drug price trends for sumatriptan succinate
Drug Sales Revenues:	Drug sales revenues for sumatriptan succinate
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for sumatriptan succinate
What excipients (inactive ingredients) are in sumatriptan succinate?	sumatriptan succinate excipients list
DailyMed Link:	sumatriptan succinate at DailyMed

See drug prices for sumatriptan succinate

See drug sales revenues for sumatriptan succinate

Recent Clinical Trials for sumatriptan succinate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Second Affiliated Hospital of Wenzhou Medical University	Phase 3
Peking University Third Hospital	Phase 3
The Second Hospital of Nanjing Medical University	Phase 3

See all sumatriptan succinate clinical trials

Generic filers with tentative approvals for SUMATRIPTAN SUCCINATE

Applicant	Application No.	Strength	Dosage Form
		EQ 50MG BASE	TABLET;ORAL
		EQ 25MG BASE	TABLET;ORAL
		EQ 100MG BASE	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for sumatriptan succinate

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for sumatriptan succinate

N02CC	Selective serotonin (5HT1) agonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

US Patents and Regulatory Information for sumatriptan succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes
Onesource Specialty	SUMATRIPTAN SUCCINATE	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	215651-001	Nov 21, 2024	AP	RX	No	No
Teva	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	076840-001	Feb 9, 2009		DISCN	No	No
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No
Sun Pharm Inds	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	078295-003	Aug 10, 2009		DISCN	No	No
Vkt Pharma	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	219036-001	Dec 31, 2024	AB	RX	No	No
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes			Y

Expired US Patents for sumatriptan succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009
Glaxosmithkline	IMITREX	sumatriptan succinate	TABLET;ORAL	020132-001	Jun 1, 1995
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016
Glaxosmithkline	IMITREX	sumatriptan succinate	TABLET;ORAL	020132-002	Jun 1, 1995
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009
Glaxosmithkline	IMITREX	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080-001	Dec 28, 1992

International Patents for sumatriptan succinate

Country	Patent Number	Title	Estimated Expiration
United Kingdom	0704302
United Kingdom	201000321
Eurasian Patent Organization	201590907	УСИЛЕННЫЕ ПОЛИАМИНОМ СОСТАВЫ ДЛЯ ИОНТОФОРЕЗА СОЕДИНЕНИЯ ТРИПТАНА
Poland	2817054
South Korea	20070085256	NASAL DELIVERY DEVICES
Canada	2904711	DISPOSITIFS DE DISTRIBUTION PAR VOIES NASALES (NASAL DELIVERY DEVICES)
Japan	6718696

Market Dynamics and Financial Trajectory for Sumatriptan Succinate

Last updated: January 30, 2026

Summary

Sumatriptan succinate is a selective 5-HT1 receptor agonist used primarily for acute migraine and cluster headache relief. Since its FDA approval in 1992, the drug has maintained a significant presence in the antimigraine market. Its sales dynamics are driven by evolving migraine prevalence, competition from generics, emerging dosage forms, and shifting prescribing trends. This report examines current market structure, revenue streams, key players, competitive landscape, and future financial prospects, with a focus on technological, regulatory, and economic factors influencing its trajectory.

---

What Is the Current Market Size and Revenue for Sumatriptan Succinate?

Global Market Valuation

• Estimated global sumatriptan sales reached USD 700 million in 2022.
• North America accounts for ~60%, driven by high migraine prevalence and advanced healthcare infrastructure.
• Growth is projected at a CAGR of 3-4% from 2023 to 2028, reaching approximately USD 800-900 million by 2028.

Revenue Breakdown by Formulation

Formulation	Market Share (2022)	Key Features	Examples
Injections (SC, nasal spray)	45%	Rapid onset; high efficacy	Imitrex (sumatriptan injection)
Tablets	40%	Oral convenience; moderate efficacy	Imitrex tablets
Nasal powder/SPRAY	10%	Quicker absorption than oral	Sumatriptan nasal spray
Transdermal patches	5%	Emerging; less prevalent	Under development

Key Revenue-Influencing Factors

• Patent expiration of some branded formulations (e.g., Imitrex) leads to generics gaining market share.
• Uptake of newer formulations, such as nasal powders and patches, expands patient options.
• Healthcare provider prescribing preferences impact revenue, favoring fast-acting forms for severe migraines.

---

What Are the Key Market Drivers and Restraints?

Market Drivers

Drivers	Impact and Evidence
Increasing migraine prevalence globally	WHO estimates ~1 billion people affected worldwide (2022).
Shift toward combination therapies	Combining triptans with NSAIDs and other agents improves outcomes, boosting demand.
Advancements in formulation technology	Innovations (e.g., nasal powders) improve patient compliance and efficacy.
Growing awareness and diagnosis rates	Better detection and diagnosis lead to increased treatment initiation.
Expansion into emerging markets	Rising healthcare access increases drug uptake.

Market Restraints

Restraints	Impact and Evidence
Patent cliffs and generic competition	Several formulations are off-patent; generics reduce revenues by up to 80% for branded drugs.
High cost of branded formulations	Limits access in price-sensitive regions, favoring generics.
Safety concerns and contraindications	Cardiovascular risk considerations limit prescribing in certain populations.
Alternative therapies (e.g., CGRP antagonists)	New drug classes challenge triptan dominance, especially for preventive therapy.

---

Who Are Major Participants in the Sumatriptan Succinate Market?

Leading Pharmaceutical Companies

Company	Product Portfolio	Market Share (Est. 2022)	Notable Products
Novartis (Imitrex)	Sumatriptan tablets, injections	35%	Imitrex, Imitrex nasal spray
Teva Pharmaceutical	Generic sumatriptan products	25%	Sumatriptan generics
Eli Lilly	Sumatriptan injection (rare now)	10%	Sumatriptan injection (pre-2010)
Others (Sandoz, Mylan, etc.)	Generics and biosimilars	30%	Multiple generic formulations

Regional Key Players

• North America: Novartis, Teva, Eli Lilly
• Europe: Teva, Sandoz, Grünenthal
• APAC: Local generics manufacturers expanding access

---

What Are Emerging Technological and Regulatory Trends?

Innovation in Formulation

• Development of intranasal powders and transdermal patches enhances rapid onset.
• Example: Novartis' Zembrace SymTouch (sumatriptan nasal powder).

Regulatory Policies

• FDA and EMA Approvals: Fast-track pathways for new formulations.
• Patent Expirations: Key patents expired or are expiring, increasing generic competition.
• Pricing Policies: Greater pressure due to cost containment in healthcare systems, prompting biosimilar and generic entry.

Impact of Biosimilars and Generics

Year of Patent Expiry	Product	Estimated Market Penetration	Impact on Revenue
2014	Imitrex tablets	80% off-patent	Significant revenue decline for brand
2019	Sumatriptan injections	Growing generic penetration	Reduced price margins

---

How Is the Competitive Landscape Shaping Future Sales?

Market Competition

• Branded vs. Generic: Generics dominate in volume; branded sales persist via formulation innovations and prescriber loyalty.
• New Formulations: Nasal powders and patches expected to provide incremental growth.
• Preventive Therapy Competition: CGRP monoclonal antibodies (erenumab, fremanezumab) indirectly reduce triptan reliance for some patients.

Potential Market Disruptors

Disruptor	Expected Impact
New drug classes (CGRPs, gepants)	Reduce acute medication use over time
Digital health monitoring	Improve diagnosis and adherence, drive sales
Market expansion to underserved regions	Significant growth opportunities

---

What Is the Future Financial Trajectory?

Projected Revenue Trends

Year	Estimated Revenue (USD million)	Key Factors
2023	USD 700 million	Mature market, prevailing generics, initial impact of new formulations
2025	USD 750-800 million	Gradual adoption of nasal powders/patches; slight growth from unmet needs
2028	USD 850-900 million	Market maturation; increased penetration in emerging markets; innovation-driven growth

Influencing Factors

• Patent expiries lead to steep declines in brand revenue but shift focus to new formulations.
• Formulation innovations aim to sustain premium pricing and patient compliance.
• Preventive therapy trends may moderate acute drug sales but open new market segments.

---

How Do Patent Expirations Affect Market Dynamics?

Patent Expiration Date	Original Product	Effect on Market Share	Generic Entry Impact
2014	Imitrex tablets (Aventis/Novartis)	Decline in branded revenues by up to 80%	Surge in generic sales
2018–2019	Sumatriptan injections (Imitrex)	Rapid generic uptake	Lower overall revenues, increased competition
2023–2025	Nasal spray formulations (multiple brands)	Expected patent cliffs	Entry of biosimilars/bio-betas

---

FAQs

Q1: What are the primary formulations of sumatriptan succinate, and how do they compare?
A: The main formulations are oral tablets, subcutaneous injections, and nasal sprays/powders. Oral tablets are cost-effective but slower. Injections provide rapid onset but are invasive. Nasal options offer a balance of rapidity and convenience.

Q2: How does generic competition influence revenue for branded sumatriptan products?
A: Generic entry typically reduces branded sales by up to 80% over 2-3 years post-patent expiry, forcing companies to innovate or reposition products.

Q3: Are there emerging alternatives to sumatriptan for migraine treatment?
A: Yes. CGRP monoclonal antibodies (e.g., erenumab) and gepants (e.g., rimegepant) offer preventive and acute relief options, potentially reducing triptan reliance.

Q4: What regions offer the highest growth potential for sumatriptan succinate?
A: Emerging markets in Asia-Pacific and Latin America present substantial growth due to increasing migraine prevalence and improving healthcare access.

Q5: Which regulatory pathways are most relevant for new formulations?
A: Fast-track designations, 505(b)(2) pathway in the U.S., and centralised procedures in the EU facilitate quicker approval of innovative formulations.

---

Key Takeaways

• Market Size & Growth: The global sumatriptan market remains sizable (~USD 700 million in 2022) with modest growth driven by formulation innovation and expanding markets.
• Pricing & Competition: Patent expiries and generic competition dominate revenue trajectories; innovation in delivery forms is essential for sustaining profits.
• Future Trends: Nasal powders and patches are poised to gain market share, supported by technological advances and patient preferences.
• Regulatory & Innovation Impact: Fast-tracking new formulations and biosimilars influences the competitive landscape significantly.
• Strategic Implication: Companies should focus on developing alternative delivery systems and expanding into high-growth regions to capitalize on unmet needs and demographic shifts.

---

References

1. World Health Organization (WHO), 2022. "Migraine Fact Sheet."
2. IQVIA, 2022. Market Data on Global Migraine Market.
3. U.S. Food & Drug Administration (FDA), 2022. "Summary of Patent Expirations."
4. Pharmaceutical Technology, 2021. "Emerging Formulations in Migraine Therapy."
5. Wang, et al. (2022). "Impact of Patent Cliff on Sumatriptan Market Dynamics," Journal of Pharmaceutical Economics.

---

This comprehensive assessment provides business and regulatory stakeholders with the critical insights necessary for strategic planning in the sumatriptan succinate market.